SBHMY (Sino Biopharmaceutical) Other Long-Term Liabilities: $132 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SBHMY Sino Biopharmaceutical Ltd SBHMY
74 GF Score
Price $14.54
GF Value $14.24
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Sino Biopharmaceutical Other Long-Term Liabilities?

Sino Biopharmaceutical SBHMY 74 Other Long-Term Liabilities is $132 Mil as of Jun. 2026. GuruFocus rates SBHMY with a GF Score™ of 74/100 and a GF Value™ of $14.24 (Fairly Valued). The stock has 3 warning signs investors should review.

Sino Biopharmaceutical's other long-term liabilities for the quarter that ended in Jun. 2026 was $132 Mil.

Sino Biopharmaceutical's quarterly other long-term liabilities declined from Jun. 2025 ($115 Mil) to Dec. 2025 ($113 Mil) but then increased from Dec. 2025 ($113 Mil) to Jun. 2026 ($132 Mil).

Sino Biopharmaceutical's annual other long-term liabilities increased from Dec. 2023 ($95 Mil) to Dec. 2024 ($104 Mil) and increased from Dec. 2024 ($104 Mil) to Dec. 2025 ($113 Mil).

Sino Biopharmaceutical Other Long-Term Liabilities Related Terms

Sino Biopharmaceutical Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Sino Biopharmaceutical's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sino Biopharmaceutical Other Long-Term Liabilities Chart

Sino Biopharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 165.57 126.61 95.00 104.09 112.57

Sino Biopharmaceutical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.34 104.09 115.12 112.57 132.06
SBHMY
74GF Score
Sino Biopharmaceutical Ltd SBHMY
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sino Biopharmaceutical Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $132 Mil mean?
Sino Biopharmaceutical (SBHMY) has a Other Long-Term Liabilities of $132 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sino Biopharmaceutical and its competitors.
Is Sino Biopharmaceutical's Other Long-Term Liabilities too high?
Sino Biopharmaceutical's current Other Long-Term Liabilities is $132 Mil. Overall, Sino Biopharmaceutical has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Other Long-Term Liabilities compare to VRTX and REGN?
Sino Biopharmaceutical's Other Long-Term Liabilities of $132 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current Other Long-Term Liabilities is $132 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBHMY) is currently considered Fairly Valued. The stock's GF Value™ is $14.24, compared to a current price of $14.54 — trading 2.1% above its estimated fair value. The current Other Long-Term Liabilities is $132 Mil. Sino Biopharmaceutical's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Sino Biopharmaceutical (SBHMY), the current Other Long-Term Liabilities is $132 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sino Biopharmaceutical (SBHMY) Overvalued in 2026?

Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be overvalued. The current stock price of $14.54 is trading 2.1% above its estimated GF Value™ of $14.24. GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.

Key valuation signals for SBHMY:

  • Other Long-Term Liabilities: $132 Mil
  • GF Value™: $14.24 vs. price of $14.54 (2.1% above fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the SBHMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sino Biopharmaceutical Business Description

Address 1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
74GF Score

Get the complete analysis for SBHMY

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.54
Price
$14.24
GF Value